Clinical trials: Aromatase Inhibitors
Breast Cancer
Impact of a Food Supplement on Musculoskeletal Pain in Women With Breast Cancer Treated With Aromatase Inhibitors.
The aim of this pilot study is to assess the change in pain, measured with the Modified Brief Pain Inventory - Short Form (mBPI-sf), at 4, 8, and 12 weeks.
- Trial name
- DOLFLEX (NCT07199556)
- Testing
- Food supplement
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Arafarma Group, S.A.
Advanced Breast Cancer
A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor
This study aimed at evaluating the safety and efficacy of everolimus plus exemestane in Chinese postmenopausal women with ER+ HER2- locally advanced, recurrent, or metastatic breast cancer after recurrence or progression on…
- Trial name
- BOLERO-5 (NCT03312738)
- Testing
- Everolimus, Exemestane
- Where
- 15 sites in China
- Volunteers
- 159 people
- Sponsor
- Novartis Pharmaceuticals
Sexual Dysfunction, Physiological
Vaginal Testosterone Cream vs ESTRING for Vaginal Dryness or Decreased Libido in Early Stage Breast Cancer Patients
The purpose of this clinical research study is to determine whether the ESTRING or a special preparation of a testosterone cream inserted vaginally are safe for use in breast cancer patients.
- Trial name
- E-String (NCT00698035)
- Testing
- Testosterone Cream, Estring
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- University of California, San Francisco
Male Breast Cancer
Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients
A prospective, randomised multi-centre phase II study evaluating the adjuvant, neoadjuvant or palliative treatment with tamoxifen +/- GnRH analogue versus aromatase inhibitor + GnRH analogue in male breast cancer patients (MALE).
- Trial name
- MALE (NCT01638247)
- Testing
- Tamoxifen, Tamoxifen and GnRH analogue, Exemestane and GnRH analogue
- Where
- Germany
- Volunteers
- 56 people
- Sponsor
- GBG Forschungs GmbH
Carpal Tunnel Syndrome (CTS) in Breast Cancer Patients
Laser Acupuncture on Carpal Tunnel Syndrome .
The study will be carried out on a total number of fifty-four females with age ranged 40 - 60 years old suffering from CTS post mastectomy ,the patients will be randomly assigned into two groups equal in number (27 patients for…
- Trial name
- NCT07405008
- Testing
- LASER acupuncture technique, Traditional physical therapy
- Where
- Egypt
- Volunteers
- 54 people
- Sponsor
- Cairo University
Breast Cancer
BREADS: Breast Adjuvant Diet Study
This is a randomized controlled trial of a 6-month extreme carbohydrate restricted diet (20 grams total carbs/day) via phone counseling with dietitian plus aromatase inhibitor therapy vs.
- Trial name
- NCT04189263
- Testing
- Carbohydrate restricted dietary intervention, standard of care aromatase inhibitors
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Farin Amersi
Breast Cancer
Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients Diagnosed With HR+/HER2 Advanced/Metastatic Breast Cancer on Palbociclib + Aromatase Inhibitor (AI) Combination Therapy
The study is designed to describe patient characteristics, treatment patterns, and clinical effectiveness outcomes in patients diagnosed with HR+/HER2- A/MBC who received palbociclib combination therapy with AI as first-line…
- Trial name
- NCT04394247
- Where
- United States
- Volunteers
- 242 people
- Sponsor
- Pfizer
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Semaglutide and Structured Lifestyle Support to Improve Heart and Blood Vessel Health in Postmenopausal Obese Breast Cancer Survivors Taking Aromatase Inhibitors
This phase IV trial studies whether adding semaglutide to structured lifestyle support improves heart and blood vessel health in postmenopausal obese breast cancer survivors (BCS) who are taking an aromatase inhibitor.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
- Trial name
- NCT07769047
- Testing
- Biospecimen Collection, Dual X-ray Absorptiometry, Functional Assessment
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Anovulation
Comparison of Anastrozole Verses Clomiphene Citrate in Stimulating Follicular Growth and Ovulation in Infertile Women With Ovulatory Dysfunction
The purpose of this study is to investigate and compare the safety and efficacy of various doses of the aromatase inhibitor (anastrozole) versus clomiphene citrate in stimulating follicular growth and ovulation in infertile women…
- Trial name
- NCT00213148
- Testing
- Anastrozole 1 mg, Anastrozole 5 mg, Anastrozole 10 mg
- Where
- United States
- Volunteers
- 271 people
- Sponsor
- EMD Serono
Neoplasms, Breast
A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer
A study to compare the safety and efficacy of an aromatase inhibitor in combination with lapatinib, trastuzumab or both for the treatment of hormone receptor positive, HER2+ metastatic breast cancer (MBC).
- Trial name
- NCT01160211
- Testing
- Lapatinib, Trastuzumab, Aromatase Inhibitor
- Where
- 110 sites in United States, Argentina and 27 more
- Volunteers
- 369 people
- Sponsor
- Novartis Pharmaceuticals
Estrogen Receptor-positive Breast Cancer, Musculoskeletal Complications
A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
E1Z11 is a study to determine whether certain genetic information can predict which breast cancer patients will discontinue treatment with aromatase inhibitors (AIs) due to the development of musculoskeletal symptoms (MSS).
- Conditions
- Estrogen Receptor-positive Breast Cancer, Musculoskeletal Complications, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT01824836
- Testing
- anastrozole
- Where
- 2 sites in United States
- Volunteers
- 1,046 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Breast Neoplasms, Musculoskeletal Pain
Hypnosis to Reduce Aromatase Inhibitor Pain and Improve Adherence
The purpose of this study is to determine whether hypnosis is efficacious in reducing musculoskeletal pain in breast cancer survivors taking aromatase inhibitors, and by doing so, whether hypnosis can help survivors to be more…
- Trial name
- NCT02657993
- Testing
- Hypnosis, Attention Control
- Where
- United States
- Volunteers
- 191 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Breast Cancer
HR+/ HER2- Advanced/ Metastatic Breast Cancer Real World Treatment Patterns and Outcomes
This is a retrospective, observational study that will document the treatment patterns and clinical outcomes of patients diagnosed with HR+/HER2- A/MBC who received CDK4/6i combination therapy with aromatase inhibitors (AI) as…
- Trial name
- NCT04396626
- Where
- United States
- Volunteers
- 975 people
- Sponsor
- Pfizer
Breast Cancer
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells.
- Trial name
- NCT00423917
- Testing
- bevacizumab, fulvestrant
- Where
- 205 sites in United States
- Volunteers
- 36 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer
A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer
This 2 arm study assessed the safety and efficacy of adding intravenous trastuzumab (Herceptin®) to daily oral anastrozole (Arimidex®) tablets as first- and second-line treatment in postmenopausal patients with human epidermal…
- Trial name
- NCT00022672
- Testing
- trastuzumab (Herceptin®), anastrazole (Arimidex®)
- Where
- 132 sites in United States, Australia and 24 more
- Volunteers
- 208 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Efficacy of Denosumab on Normal BMD in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast Cancer
This multicenter, randomized, comparative study will evaluate the efficacy of denosumab to prevent the adjuvant therapy of aromatase inhibitors-induced loss of bone mineral density (BMD) in breast cancer patients with normal BMD.
- Trial name
- NCT03324932
- Testing
- Denosumab Injection
- Where
- Japan
- Volunteers
- 160 people
- Sponsor
- Kyoto Prefectural University of Medicine
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8
High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer
This phase II trial tests the effectiveness of cannabidiol (CBD) plant extract (BRC-001) in improving joint stiffness and pain (arthralgia) in women with breast cancer taking aromatase inhibitors (AIs).
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
- Trial name
- NCT06538389
- Testing
- Biospecimen Collection, BRC-001, Questionnaire Administration
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- City of Hope Medical Center
Obesity
Influence of Aromatase Inhibition on Hepatic- and Cardiac Function in Severe Obese Men
It seems plausible that increased aromatase activity in obese men, as a result of a larger fat mass, is responsible for decreased levels of testosterone.
- Trial name
- HEPAROB (NCT02097680)
- Testing
- Letrozole
- Where
- Belgium
- Volunteers
- 30 people
- Sponsor
- University Hospital, Ghent
Breast Cancer, Pain
Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer Patients
Postmenopausal women who have hormone receptor positive breast cancer are typically treated with aromatase inhibitor medications, which substantially decrease the amount of estrogen produced by their bodies.
- Conditions
- Breast Cancer, Pain, Arthralgia
- Trial name
- NCT01814397
- Testing
- Anastrozole, exemestane, letrozole
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Michigan Rogel Cancer Center
Breast Cancer
Oral Aromatase Inhibitors Modify the Gut Microbiome
The purpose of this research is to study the bacteria in participants' gut before receiving a medicine called an aromatase inhibitor for breast cancer and after participants receive medicine for breast cancer.
- Trial name
- NCT05030038
- Testing
- Fecal swab collection, Blood samples
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Wake Forest University Health Sciences